Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
53
XENE Quote, Financials, Valuation and Earnings
Last price:
$45.00
Seasonality move
:
15.12%
Day range:
$44.56 - $45.38
52-week range:
$26.74 - $46.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
473.02x
P/B ratio:
6.22x
Volume:
295.4K
Avg. volume:
808.9K
1-year change:
17.15%
Market cap:
$3.5B
Revenue:
--
EPS (TTM):
-$3.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.16 | -- | -43.57% | $55.40 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $5.33 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -13.85% | $5.55 |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -- | -- | -- | $105.58 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.40 | $3.5B | -- | $0.00 | 0% | 473.02x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$16.29 | $16.67 | $2.1B | 29.03x | $0.00 | 0% | 8.65x |
|
EDSA
Edesa Biotech, Inc.
|
$1.30 | $11.00 | $9.1M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.56 | $5.33 | $13.9M | -- | $0.00 | 0% | 14.29x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.55 | $104.4M | -- | $0.00 | 0% | -- |
|
PMN
ProMIS Neurosciences, Inc.
|
$8.27 | $105.58 | $17.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -0.093 | -- | 1.26x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -$11.8M | -348.3% | -348.3% | -- | -$10.2M |
Xenon Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns XENE or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -867.29% compared to Xenon Pharmaceuticals, Inc.'s net margin of 42.95%. Xenon Pharmaceuticals, Inc.'s return on equity of -44.39% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About XENE or AUPH?
Xenon Pharmaceuticals, Inc. has a consensus price target of $55.40, signalling upside risk potential of 23.09%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.82%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XENEXenon Pharmaceuticals, Inc.17 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is XENE or AUPH More Risky?
Xenon Pharmaceuticals, Inc. has a beta of 1.027, which suggesting that the stock is 2.689% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock XENE or AUPH?
Xenon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XENE or AUPH?
Xenon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Xenon Pharmaceuticals, Inc.'s net income of -$90.9M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Xenon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals, Inc. is 473.02x versus 8.65x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M AUPHAurinia Pharmaceuticals, Inc.8.65x 29.03x $73.5M $31.6M
-
Which has Higher Returns XENE or EDSA?
Edesa Biotech, Inc. has a net margin of -867.29% compared to Xenon Pharmaceuticals, Inc.'s net margin of --. Xenon Pharmaceuticals, Inc.'s return on equity of -44.39% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About XENE or EDSA?
Xenon Pharmaceuticals, Inc. has a consensus price target of $55.40, signalling upside risk potential of 23.09%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XENEXenon Pharmaceuticals, Inc.17 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is XENE or EDSA More Risky?
Xenon Pharmaceuticals, Inc. has a beta of 1.027, which suggesting that the stock is 2.689% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock XENE or EDSA?
Xenon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XENE or EDSA?
Xenon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Xenon Pharmaceuticals, Inc.'s net income of -$90.9M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Xenon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals, Inc. is 473.02x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns XENE or LEXX?
Lexaria Bioscience Corp. has a net margin of -867.29% compared to Xenon Pharmaceuticals, Inc.'s net margin of -2178.51%. Xenon Pharmaceuticals, Inc.'s return on equity of -44.39% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About XENE or LEXX?
Xenon Pharmaceuticals, Inc. has a consensus price target of $55.40, signalling upside risk potential of 23.09%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XENEXenon Pharmaceuticals, Inc.17 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is XENE or LEXX More Risky?
Xenon Pharmaceuticals, Inc. has a beta of 1.027, which suggesting that the stock is 2.689% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock XENE or LEXX?
Xenon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XENE or LEXX?
Xenon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Xenon Pharmaceuticals, Inc.'s net income of -$90.9M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Xenon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals, Inc. is 473.02x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M LEXXLexaria Bioscience Corp.14.29x -- $174K -$2.7M
-
Which has Higher Returns XENE or ONCY?
Oncolytics Biotech, Inc. has a net margin of -867.29% compared to Xenon Pharmaceuticals, Inc.'s net margin of --. Xenon Pharmaceuticals, Inc.'s return on equity of -44.39% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About XENE or ONCY?
Xenon Pharmaceuticals, Inc. has a consensus price target of $55.40, signalling upside risk potential of 23.09%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XENEXenon Pharmaceuticals, Inc.17 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is XENE or ONCY More Risky?
Xenon Pharmaceuticals, Inc. has a beta of 1.027, which suggesting that the stock is 2.689% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock XENE or ONCY?
Xenon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XENE or ONCY?
Xenon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Xenon Pharmaceuticals, Inc.'s net income of -$90.9M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Xenon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals, Inc. is 473.02x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns XENE or PMN?
ProMIS Neurosciences, Inc. has a net margin of -867.29% compared to Xenon Pharmaceuticals, Inc.'s net margin of --. Xenon Pharmaceuticals, Inc.'s return on equity of -44.39% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.
Company Gross Margin Earnings Per Share Invested Capital XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M -
What do Analysts Say About XENE or PMN?
Xenon Pharmaceuticals, Inc. has a consensus price target of $55.40, signalling upside risk potential of 23.09%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $105.58 which suggests that it could grow by 1176.68%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XENEXenon Pharmaceuticals, Inc.17 0 0 PMNProMIS Neurosciences, Inc.2 0 0 -
Is XENE or PMN More Risky?
Xenon Pharmaceuticals, Inc. has a beta of 1.027, which suggesting that the stock is 2.689% more volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 105.015%.
-
Which is a Better Dividend Stock XENE or PMN?
Xenon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XENE or PMN?
Xenon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Xenon Pharmaceuticals, Inc.'s net income of -$90.9M is lower than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Xenon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals, Inc. is 473.02x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
